Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Tricia R. Cottrell(Queen's University), Janis M. Taube(Bloomberg (United States)), Stephen C. Yang(Johns Hopkins University), Robert A. Anders(Johns Hopkins University), Matthew D. Hellmann(AstraZeneca (United States)), Jonathan D. Cuda(Cabell Huntington Hospital), Peter B. Illei(Johns Hopkins University), Ashley Cimino‐Mathews(Bloomberg (United States)), Amy S. Duffield(Johns Hopkins University), Suzanne L. Topalian(Bloomberg (United States)), Jedd D. Wolchok(Cornell University), Valsamo Anagnostou(Johns Hopkins University), Frederic B. Askin(Johns Hopkins University), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Jennifer L. Sauter(Memorial Sloan Kettering Cancer Center), David R. Jones(Memorial Sloan Kettering Cancer Center), Drew M. Pardoll(Bloomberg (United States)), Elizabeth D. Thompson(Bloomberg (United States)), Natasha Rekhtman(Memorial Sloan Kettering Cancer Center), Noushin Niknafs(Johns Hopkins University), Julie E. Stein(Johns Hopkins University), Kellie N. Smith(Bloomberg (United States)), James M. Isbell(Memorial Sloan Kettering Cancer Center), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), L. Danilova(Bloomberg (United States)), Moises J. Velez(Memorial Sloan Kettering Cancer Center), E Gabrielson(Johns Hopkins University), Victor E. Velculescu(Johns Hopkins University), Richard J. Battafarano(Johns Hopkins University), Julie R. Brahmer(Johns Hopkins University)

Annals of Oncology

June 13, 2018

Cited by 588

Related Papers

|New England Journal of Medicine|2012|12.6k

|Nature|2013|10.1k

|New England Journal of Medicine|2015|9.4k

|Science|2013|8k

|New England Journal of Medicine|2012|8k